Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
=== Protecting groups === As a class, esters serve as protecting groups for carboxylic acids. Protecting a carboxylic acid is useful in peptide synthesis, to prevent self-reactions of the bifunctional amino acids. Methyl and ethyl esters are commonly available for many amino acids; the t-butyl ester tends to be more expensive. However, t-butyl esters are particularly useful because, under strongly acidic conditions, the t-butyl esters undergo elimination to give the carboxylic acid and isobutylene, simplifying work-up.
Controlled animal and human studies showed that caffeine (energy drinks) in combination with alcohol increased the craving for more alcohol more strongly than alcohol alone. These findings correspond to epidemiological data that people who consume energy drinks generally showed an increased tendency to take alcohol and other substances.
Starmer attends a UK–Ireland summit in Liverpool alongside Taoiseach Micheál Martin at which he says the two countries have "turned a page on the turbulent years" and are ready for a meaningful partnership. Conservative peer Lord Hamilton apologises after saying the Jewish community should "pay for their own" Holocaust memorial because they have "an awful lot of money" during a House of Lords debate on plans for a memorial near Parliament. 7 March – Reform UK suspends MP Rupert Lowe from the party and refers him to police, alleging he has made "threats of physical violence" against party chairman Zia Yusuf. Former Liverpool mayor Joe Anderson and city politician Derek Hatton are charged with bribery and misconduct relating to council contracts, along with 10 others. Former Secretary of State for Wales Simon Hart says that Mark Drakeford, the country's First Minister during the COVID-19 pandemic, "dented people's confidence" in the UK government by saying successful aspects of the fight against COVID were Welsh Government policy and the unsuccessful were UK government policy. 8 March – Former national security adviser Mark Sedwill tells the BBC's The Week at Westminster the potential deployment of UK troops to Ukraine could last "many years". 10 March – Mike Amesbury confirms he will stand down as the MP for Runcorn and Helsby following his conviction for assault, triggering a by-election. Home Secretary Yvette Cooper rejects calls from the family of David Amess for a public inquiry into his murder. Former Labour MP Thangam Debbonaire is introduced into the House of Lords.
Sources: en.wikipedia.org
The rectal route is an effective route of administration for many medications, especially those used at the end of life. The walls of the rectum absorb many medications quickly and effectively. Medications delivered to the distal one-third of the rectum at least partially avoid the "first pass effect" through the liver, which allows for greater bio-availability of many medications than that of the oral route. Rectal mucosa is highly vascularized tissue that allows for rapid and effective absorption of medications. A suppository is a solid dosage form that fits for rectal administration. In hospice care, a specialized rectal catheter, designed to provide comfortable and discreet administration of ongoing medications provides a practical way to deliver and retain liquid formulations in the distal rectum, giving health practitioners a way to leverage the established benefits of rectal administration. The Murphy drip is an example of rectal infusion.
== Leidenfrost temperature and surface tension effects == The Leidenfrost temperature is the property of a given set of solid–liquid pair. The temperature of the solid surface beyond which the liquid undergoes the Leidenfrost phenomenon is termed the Leidenfrost temperature. Calculation of the Leidenfrost temperature involves the calculation of the minimum film boiling temperature of a fluid. Berenson obtained a relation for the minimum film boiling temperature from minimum heat flux arguments. While the equation for the minimum film boiling temperature, which can be found in the reference above, is quite complex, the features of it can be understood from a physical perspective. One critical parameter to consider is the surface tension. The proportional relationship between the minimum film boiling temperature and surface tension is to be expected, since fluids with higher surface tension need higher quantities of heat flux for the onset of nucleate boiling. Since film boiling occurs after nucleate boiling, the minimum temperature for film boiling should have a proportional dependence on the surface tension. Henry developed a model for the Leidenfrost phenomenon which includes transient wetting and microlayer evaporation. Since the Leidenfrost phenomenon is a special case of film boiling, the Leidenfrost temperature is related to the minimum film boiling temperature via a relation which factors in the properties of the solid being used.
Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful.
10 October – After making contact with his parents-in-law in Gaza, Humza Yousaf calls for a humanitarian corridor to be established. 11 October – Sean Hogg, who was given a 270-hour community order after being found guilty of twice raping a 13-year-old girl when he was 17, has the conviction quashed on appeal after prosecutors admit making mistakes during the original trial. Police are investigating fresh revelations about the Bible John killings after a podcast, Bible John: Portrait of the Serial Killer, alleged a cover up by police at the time, and that the perpetrator could be John Irvine McInnes, the cousin of a senior police officer. 12 October – Lisa Cameron, MP for East Kilbride, Strathaven and Lesmahagow, crosses the floor from the SNP to the Conservatives citing "a "toxic" culture in the SNP's Westminster group". Edinburgh Sheriff Court orders the extradition of Holocaust denier Vincent Reynouard, who faces trial in France for challenging the existence of crimes against humanity. Aberdeen City Councillor Kairin van Sweeden refers herself to the Standards Commission after describing a fellow councillor who was born in Sri Lanka as a "New Scot" during a council meeting. 13 October – After sharing a video of his mother-in-law, Elizabeth El-Nakla, describing the situation in Gaza, First Minister Humza Yousaf says that Israel is "going too far" and that innocent civilians can not simply be "collateral damage".
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.